This HTML5 document contains 89 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00939/identifier/chemspider/
n23http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00939/identifier/wikipedia/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00939/identifier/pharmgkb/
n9http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00939/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00939/identifier/bindingdb/
n25http://www.rxlist.com/cgi/generic/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00939/identifier/pubchem-compound/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00939/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00939/identifier/kegg-drug/
n22http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00939/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00939/identifier/national-drug-code-directory/
n7http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00939
rdf:type
n3:Drug
n3:description
A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. [PubChem]
n3:dosage
n26:271B3F31-363D-11E5-9242-09173F13E4C5 n26:271B3F30-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.
n3:indication
For the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss. Also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis.
n3:manufacturer
n5:271B3F2C-363D-11E5-9242-09173F13E4C5 n5:271B3F2D-363D-11E5-9242-09173F13E4C5 n5:271B3F2A-363D-11E5-9242-09173F13E4C5 n5:271B3F2B-363D-11E5-9242-09173F13E4C5 n5:271B3F28-363D-11E5-9242-09173F13E4C5 n5:271B3F29-363D-11E5-9242-09173F13E4C5 n5:271B3F26-363D-11E5-9242-09173F13E4C5 n5:271B3F27-363D-11E5-9242-09173F13E4C5 n5:271B3F2E-363D-11E5-9242-09173F13E4C5 n5:271B3F2F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00939 n21:DB00939
dcterms:title
Meclofenamic acid
adms:identifier
n11:22971 n12:3897 n13:46507887 n14:PA450341 n15:4037 n16:D02341 n17:0378-2150-01 n18:DB00939 n19:C02996 n27:Meclofenamic_acid
n3:mechanismOfAction
The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamic acid was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro meclofenamic acid was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamic acid. There is no evidence that meclofenamic acid alters the course of the underlying disease.
n3:packager
n5:271B3F20-363D-11E5-9242-09173F13E4C5 n5:271B3F21-363D-11E5-9242-09173F13E4C5 n5:271B3F24-363D-11E5-9242-09173F13E4C5 n5:271B3F25-363D-11E5-9242-09173F13E4C5 n5:271B3F22-363D-11E5-9242-09173F13E4C5 n5:271B3F23-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Other metabolites, whose excretion rates are unknown, account for the remaining 35% to 62% of the dose excreted in the urine. The remainder of the administered dose (approximately 30%) is eliminated in the feces (apparently through biliary excretion). Trace amounts of meclofenamate sodium are excreted in human breast milk.
n3:synonym
Acide meclofenamique N-(2,6-Dichloro-3-methylphenyl)anthranilic acid CI-583 INF 4668 N-(2,6-Dichloro-m-tolyl)anthranilic acid Acido meclofenamico Acidum meclofenamicum Meclofenamate N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid
n3:toxicity
After a massive overdose, CNS stimulation may be manifested by irrational behavior, marked agitation and generalized seizures. Following this phase, renal toxicity (falling urine output, rising creatinine, abnormal urinary cellular elements) may be noted with possible oliguria or anuria and azotemia. A 24 year-old male was anuric for approximately one week after ingesting an overdose of 6 to 7 grams of meclofenamate sodium. Spontaneous diuresis and recovery subsequently occurred.
n3:volumeOfDistribution
* 9.1 to 43.2 L
n3:proteinBinding
Greater than 99% bound to plasma proteins over a wide drug concentration range.
n3:synthesisReference
U.S. Patent 3,313,848.
n22:hasConcept
n23:M0013184
foaf:page
n25:meclofen.htm
n3:IUPAC-Name
n4:271B3F36-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3F3C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3F3B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3F38-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3F39-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3F3A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3F4C-363D-11E5-9242-09173F13E4C5 n4:271B3F34-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3F4E-363D-11E5-9242-09173F13E4C5 n4:271B3F32-363D-11E5-9242-09173F13E4C5 n4:271B3F35-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3F33-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:M01AG04 n7:M02AA18
n3:H-Bond-Acceptor-Count
n4:271B3F42-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3F43-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3F3D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3F3E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3F40-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3F3F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3F41-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed in man following single and multiple oral doses with peak plasma concentrations occurring in 0.5 to 2 hours. The concomitant administration of antacids (aluminum and magnesium hydroxides) does not interfere with absorption of meclofenamic acid. Unlike most NSAIDs, which when administered with food have a decrease in rate but not in extent of absorption, meclofenamic acid is decreased in both. It has been reported that following the administration of meclofenamic acid capsules one-half hour after a meal, the average extent of bioavailability decreased by 26%, the average peak concentration (C<sub>max</sub>) decreased fourfold and the time to C<sub>max</sub> was delayed by 3 hours.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
644-62-2
n3:category
n3:clearance
* Oral cl=206 mL/min
n3:Bioavailability
n4:271B3F48-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3F4A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3F4B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B3F4D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3F47-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3F46-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3F49-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3F37-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B3F44-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3F45-363D-11E5-9242-09173F13E4C5